162997-34-4

Basic information

• Product Name: 4-(PIPERIDIN-4-YL)BENZONITRILE HYDROCHLORIDE
• Synonyms: 4-(PIPERIDIN-4-YL)BENZONITRILE HYDROCHLORIDE;4-Piperidin-4-ylbenzonitrile;EOS-61296
• CAS NO: 162997-34-4
• Molecular Formula: C₁₂H₁₄N₂*ClH
• Molecular Weight: 222.7139
• Mol File: 162997-34-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 333.6 °C at 760 mmHg
• Flash Point: 155.6 °C
• Appearance: /
• Density: 1.08 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-(PIPERIDIN-4-YL)BENZONITRILE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PIPERIDIN-4-YL)BENZONITRILE HYDROCHLORIDE(162997-34-4)
• EPA Substance Registry System: 4-(PIPERIDIN-4-YL)BENZONITRILE HYDROCHLORIDE(162997-34-4)

Safety Data

• Hazardous Substances Data: 162997-34-4(Hazardous Substances Data)

Upstream product

• 162997-33-3 tert-butyl 4-(4-cyanophenyl)piperidine-1-carboxylate 
• 589-87-7 1,4-bromoiodobenzene 
• 1438394-24-1 N-benzyl-1-oxo-N-(penta-3,4-dien-1-yl)indane-2-carboxamide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 163209-96-9 tert-butyl 4-(4-bromophenyl)-4-hydroxypiperidine-1-carboxylate 
• 871112-38-8 tert-butyl 4-(4-cyanophenyl)-4-hydroxypiperidine-1-carboxylate 
• 460365-08-6 4-(4-cyanophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 301673-14-3 tert-butyl 4-iodopiperidine-1-carboxylate 
• 623-00-7 4-bromobenzenecarbonitrile 

Downstream Products

• 1399177-15-1 4-(1-(2,4-dimethyl-5-(5-((tetrahydrofuran-3-yl)methyl)-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399177-27-5 4-(1-(4-cyclopropyl-5-(5-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399177-32-2 4-(1-(4-ethyl-5-(5-(2-methoxyethyl)-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399177-37-7 2 
• 1399177-66-2 4-(1-(4-cyclobutyl-2-ethyl-5-(5-ethyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399177-81-1 4-(1-(2-isopropyl-5-(5-(methoxymethyl)-4H-1,2,4-triazol-3-yl)-4-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399177-82-2 4-(1-(5-(5-(methoxymethyl)-4H-1,2,4-triazol-3-yl)-4-methyl-2-propylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399177-83-3 4-(1-(4-isopropyl-5-(5-(2-methoxyethyl)-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399177-87-7 4-(1-(4-cyclobutyl-2-methyl-5-(4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399177-94-6 4-(1-(2,4-diethyl-5-(5-(2-methoxyethyl)-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile 
• 1399178-04-1 4-(1-(4-cyclobutyl-5-(5-ethoxy-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-07-4 4-(1-(4-cyclobutyl-5-(5-methoxy-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-16-5 4-(1-(4-(3,3-difluorocyclobutyl)-5-(5-ethyl-4H-1,2,4-triazol-3-yl)-2-methylbenzoyl)piperidin-4-yl)benzonitrile 
• 1399178-17-6 2-(5-(4-(4-cyanophenyl)piperidine-1-carbonyl)-2,4-dimethylphenyl)-N,N-dimethyl-1H-imidazole-5-carboxamide 

Relevant articles and documents

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

Imidazopyridine-based fatty acid synthase inhibitors that show anti-HCV activity and in vivo target modulation

Potent imidazopyridine-based inhibitors of fatty acid synthase (FASN) are described. The compounds are shown to have antiviral (HCV replicon) activities that track with their biochemical activities. The most potent analogue (compound 19) also inhibits rat FASN and inhibits de novo palmitate synthesis in vitro (cell-based) as well as in vivo.

Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

The invention relates to carboxylic acid derivatives of general formula wherein A to G are defined as in claim 1, the tautomers thereof, the stereoisomers thereof including the mixtures thereof and the addition salts thereof, particularly the physiologically acceptable salts with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably inhibitory effects on aggregation, and to pharmaceutical compositions containing the compounds and processes for preparing them.